Related Experiment Videos
The effect of short-term and chronic immunosuppression on Theiler's virus demyelination
Abstract:
Theiler's virus (TV)-infected mice were treated with antithymocyte serum (ATS), cyclophosphamide or pepstatin (a protease inhibitor) to determine the effect on demyelination. When ATS and cyclophosphamide were begun at the time of infection there was significantly less demyelination at 2.5-3.5 weeks than in pepstatin or non-treated infected controls. When immunosuppression was continued for 5 weeks, or when it was not started until 5 weeks post-infection, no significant decrease in demyelination was seen compared to controls. The findings indicate that timing of immunosuppression is critical in determining the extent of TV demyelination. Such demyelination may occur by different mechanisms that are active at different times. The "bystander effect' may be important in early demyelination, but late demyelination may be due to other causes, such as oligodendrocyte lytic infection.
Insights
Early immunosuppression significantly reduced demyelination in Theiler's virus (TV)-infected mice. However, delaying treatment or extending it did not alter demyelination, suggesting critical timing for intervention.
Area of Science:
- Neuroimmunology
- Virology
- Demyelinating Diseases
Background:
- Theiler's virus (TV) infection in mice serves as a model for studying viral-induced demyelination.
- Understanding the mechanisms of demyelination is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the impact of immunosuppression timing on demyelination in Theiler's virus infection.
- To explore potential differences in demyelination mechanisms at various stages of infection.
Main Methods:
- Mice infected with Theiler's virus were treated with immunosuppressants (antithymocyte serum, cyclophosphamide) or a protease inhibitor (pepstatin).
- Treatment initiation and duration were varied to assess their effects on demyelination.
- Demyelination levels were compared between treated and non-treated infected control groups.
Main Results:
- Early administration of antithymocyte serum or cyclophosphamide at the time of infection significantly reduced demyelination.
- Continuing immunosuppression for 5 weeks or initiating it 5 weeks post-infection did not significantly decrease demyelination.
- Pepstatin treatment showed no significant difference in demyelination compared to controls.
Conclusions:
- The timing of immunosuppressive therapy is critical for mitigating demyelination in Theiler's virus infection.
- Early intervention may target mechanisms like the 'bystander effect,' while later demyelination might involve oligodendrocyte lytic infection.